Clinical Trial Update: Conatumumab, Gemcitabine Hydrochloride, Capecitabine, and Radiation Therapy in Treating Patients With Locally Advanced Pancreatic Cancer [Phase 1, Phase 2]

View source ↗

Summary

The trial investigating conatumumab with gemcitabine, capecitabine, and radiation therapy for locally advanced pancreatic cancer has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Cancer

Drugs mentioned

• Capecitabine (capecitabine)
• Conatumumab (conatumumab)
• Gemcitabine (Gemcitabine)

Snippet

Sponsor: Radiation Therapy Oncology Group | Conditions: Pancreatic Cancer | Phase 1, Phase 2 | Status: WITHDRAWN